Evotec Shares Plunge on Drastic Forecast Downgrade

Investors have delivered a harsh verdict on Evotec SE’s latest strategic update. The Hamburg-based biotechnology services firm saw its equity value plummet after slashing its financial guidance, despite announcing a major new restructuring initiative designed to restore stability.

Market Reaction Overshadows “Horizon” Restructuring Plan

The company’s newly unveiled “Horizon” transformation program, intended to address persistent weaknesses in its core operations, was completely overshadowed by a severe profit warning. Management now anticipates an adjusted EBITDA for 2026 of just €0 to €40 million. This range falls drastically short of analyst consensus estimates, which had been projecting over €80 million. The forecast has laid bare the serious challenges facing the company’s current earnings power.

Furthermore, the revenue outlook for the coming year suggests, at best, a period of stagnation. Evotec guided for 2026 sales between €700 million and €780 million, which aligns closely with the preliminary figures reported for the prior year.

Deep Cost-Cutting Amid Operational Divergence

The “Horizon” plan itself involves a radical overhaul. Evotec will eliminate up to 800 positions and consolidate its global footprint to just ten sites. The goal is to achieve annual cost savings of approximately €75 million by the end of 2027. However, these future benefits will be preceded by significant near-term restructuring charges.

Should investors sell immediately? Or is it worth buying Evotec?

Operationally, the company’s performance is split. The traditional research services business is contracting and has slipped into a loss. In contrast, the Biologics division provided a lone bright spot, reporting revenue growth of roughly 40%. This strength in one segment proved insufficient to reassure the market.

Share Price Collapse and Legal Scrutiny

The financial community’s response was swift and severe. Evotec’s stock price collapsed by more than 24% within a single week. By the week’s close, shares had hit a new 52-week low of exactly €4.14. Compounding the fundamental business concerns, the steep decline has attracted the attention of US law firms. Several are reportedly investigating potential legal claims on behalf of shareholders in the wake of the crash.

Looking beyond the immediate crisis, the firm maintains its long-term ambition to achieve group revenue exceeding €1 billion by 2030. For the market to begin pricing in this vision once more, management must first demonstrate tangible operational stability. The next key milestone for investors will arrive on April 8, when Evotec is scheduled to release its final audited results for the previous fiscal year.